AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9856368
Drug: verapamil (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil (240 mg once a day)
Trial: 9856368
Drug: chlorthalidone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chlorthalidone (25 mg once a day)
Trial: 8873633
Drug: Pentoxifylline therapy
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline therapy
Trial: 25495719
Drug: Doxazosin 4
RxNorm normalized name: doxazosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 4 mg daily for 12 weeks
Trial: 25495719
Drug: Tolterodine 4
RxNorm normalized name: tolterodine 4 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 4 mg daily for 12 weeks
Trial: 20082737
Drug: High-flavanol cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flavanol cocoa beverage (701 mg)
Trial: 20082737
Drug: Low-flavanol cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flavanol cocoa beverage (22 mg)
Trial: 19057628
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of 6 mg non‐particulate Celestone
Trial: 19057628
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections (both groups)
Trial: 10897159
Drug: LEV 3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV 3,000 mg
Trial: 8604240
Drug: 6 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (10 mg/m2), and fluorouracil (500 mg/m2; CNF)
Trial: 1420740
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine administered at bedtime
Trial: 1420740
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine administered post evening meal
Trial: 29882843
Drug: WBE111 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WBE111 (100 mg)
Trial: 27418883
Drug: BCAA (0.17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA (0.17 g/kg), arginine (0.05 g/kg), citrulline (0.05 g/kg)
Trial: 20979906
Drug: Parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 40 mg by muscle injection
Trial: 20979906
Drug: 0.9% normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline 2 ml
Trial: 18783360
Drug: Interventional pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventional pain therapies
Trial: 12147929
Drug: ACE inhibitor/HCTZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor/HCTZ combinations
Trial: 10358862
Drug: Diovan (valsartan)
RxNorm normalized name: valsartan Oral Tablet [Diovan]
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Diovan (valsartan) 80 mg/day for 8 weeks, increased to 160 mg/day if needed
Trial: 1782973
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate 100 mg
Trial: 1782973
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate 100 mg with quinidine sulphate 50 mg pretreatment
Trial: 1782973
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate 100 mg in PM
Trial: 1782973
Drug: Quinidine sulphate
RxNorm normalized name: Quinidine sulphate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine sulphate 50 mg
Trial: 938185
Drug: Drug alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug alone
Trial: 6113821
Drug: Psychotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy plus drug
Trial: 23715753
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec 200 units/mL once daily
Trial: 23715753
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 units/mL once daily
Trial: 19270299
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp‐SP) with community-based promotional activities
Trial: 19270299
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp‐SP) without community-based promotional activities
Trial: 19270299
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp‐SP) during low transmission season
Trial: 15516639
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral iron supplementation (2 mg/kg/day)
Trial: 11226441
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 100 microg, repeated once after 6 h if not in active labor
Trial: 11226441
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two doses of vitamin C after a 6-h interval)
Trial: 2663518
Drug: Tobramycin in
RxNorm normalized name: tobramycin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin in combination with ampicillin
Trial: 2663518
Drug: Ceftazidime in
RxNorm normalized name: ceftazidime Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime in combination with ampicillin
Trial: 31254718
Drug: Sodium nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium nitrite (0.6 mg/kg/h)
Trial: 28409508
Drug: Caffeine supplementation
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine supplementation (6 mg.kg-1 30 minutes before tests)
Trial: 27966504
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) as an adjunct to scaling and root planing (SRP)
Trial: 22870302
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride solution (5%)
Trial: 22870302
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride solution (1% or 2%)
Trial: 18808624
Drug: Si‐Wu‐Tang (SWT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Si‐Wu‐Tang (SWT) 15 g daily for seven consecutive days after cessation of menstrual bleeding
Trial: 18808624
Drug: Si‐Wu‐Tang (SWT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Si‐Wu‐Tang (SWT) 15 g daily as soon as menstrual bleeding is noted
Trial: 9058001
Drug: Comparison group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison group (various other therapies including speech therapy and occupational therapy)
Trial: 2887186
Drug: Metoprolol (243
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (243 +/- 26 mg daily)
Trial: 2887186
Drug: Propranolol (149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (149 +/- 16 mg daily)
Trial: 2887186
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 +/- 8 mg daily)
Trial: 2919849
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (10 mg)
Trial: 2919849
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (20 mg)
Trial: 28465224
Drug: Shoe orthotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shoe orthotics plus chiropractic treatment
Trial: 28465224
Drug: Waitlist group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist group (no treatment)
Trial: 23114033
Drug: Fluoride followed
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride followed by laser treatment
Trial: 19537524
Drug: DoloVisano Methocarbamol
RxNorm normalized name: Methocarbamol
DrugBank: Methocarbamol (DB00423)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DoloVisano Methocarbamol 750 mg (test product)
Trial: 15515038
Drug: 20 min
RxNorm normalized name: wheat germ oil 20 minim ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 min daily exposure to static magnetic fields (4 patients)
Trial: 15515038
Drug: 70 min
RxNorm normalized name: TITANIUM DIOXIDE 44.26 mg in 1 mL / ZINC OXIDE 50.3 mg in 1 mL TOPICAL LOTION [Australian Gold Botanicals Sunscreen 70 Minerals]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 min daily exposure to static magnetic fields (7 patients)
Trial: 9335514
Drug: Taxoid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxoid therapy (combination with various chemotherapeutic agents and monoclonal antibodies)
Trial: 9335514
Drug: Taxoid monotherapy
RxNorm normalized name: DIPHTHERIA TOXOID
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxoid monotherapy or combination therapy
Trial: 2906873
Drug: Ramixotidine 750
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramixotidine 750 mg (CM 57755A)
Trial: 28502786
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) and Graded Exercise Therapy (GET) for 12 weeks
Trial: 18320559
Drug: Olanzapine treatment
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine treatment for 6 weeks
Trial: 12904191
Drug: Group L10F25
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L10F25 (10 mg lidocaine plus 25 microg fentanyl)
Trial: 12904191
Drug: Group L10F25E15
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L10F25E15 (10 mg lidocaine plus 25 microg fentanyl plus 15 microg epinephrine)
Trial: 12904191
Drug: Group L20F25
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L20F25 (20 mg lidocaine plus 25 microg fentanyl)
Trial: 9049593
Drug: Boswellia serrata
RxNorm normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boswellia serrata gum resin (350 mg thrice daily for 6 weeks)
Trial: 9049593
Drug: Sulfasalazine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (1 g thrice daily)
Trial: 3519694
Drug: Isocarboxazid (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocarboxazid (50 mg)
Trial: 30557404
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (1,000 IU/day) and Calcium (1,200 mg/day)
Trial: 28475205
Drug: Systemic ELF‐MF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic ELF‐MF therapy (100 microtesla, 1 to 80 Hz)
Trial: 28475205
Drug: ELF‐MF therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELF‐MF therapy
Trial: 23812596
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (Zol) 5 mg intravenous once yearly
Trial: 22490477
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil 100 mg intravenously 15 minutes before incision (PA group)
Trial: 21284135
Drug: Sustained-release bupropion
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release bupropion monotherapy (switching strategy)
Trial: 21284135
Drug: Sustained-release bupropion
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release bupropion plus citalopram (combination strategy)
Trial: 12213507
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) treatment programme for 12 weeks
Trial: 20184287
Drug: Emoxipine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emoxipine (150 mg, i.v., daily) for 14 days
Trial: 20184287
Drug: Reamberin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reamberin (400 ml, i.v., daily) for 14 days
Trial: 20184287
Drug: Mexidol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexidol (300 mg, i.v., daily) for 14 days
Trial: 16142873
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg subcutaneous injection twice weekly for 24 weeks
Trial: 10440621
Drug: Single-dose sparfloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose sparfloxacin (400 mg on day 1)
Trial: 10440621
Drug: 3-day sparfloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day sparfloxacin (400 mg loading dose on day 1 followed by 200 mg once daily for 2 additional days)
Trial: 10440621
Drug: 7-day ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-day ciprofloxacin (250 mg twice daily for 7 days)
Trial: 1495785
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (800 mg 5 times daily) for 7 days
Trial: 1495785
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (800 mg 5 times daily) for 14 days
Trial: 6496206
Drug: Reactive condition
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactive condition (telephone contact by an assistant in the original smoking cessation treatment program)
Trial: 27084538
Drug: Oral elemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral elemental diet (ED) - 300 kcal of ED plus regular diet for 6-8 weeks after surgery
Trial: 27084538
Drug: Oral elemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral elemental diet (ED) - in total gastrectomy patients
Trial: 23710734
Drug: Boceprevir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boceprevir plus peginterferon alfa-2b/ribavirin (triple therapy)
Trial: 23710734
Drug: Boceprevir (t.d.s.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boceprevir (t.d.s. dosing interval 7-9 h)
Trial: 7796899
Drug: The pill
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pill
Trial: 2084879
Drug: Nicardipine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (40 or 60 mg)
Trial: 2084879
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 or 30 mg)
Trial: 25361222
Drug: Ghrelin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin (0.5 μg/kg/h) for 5 days
Trial: 21161666
Drug: Carbohydrate-electrolyte solution
RxNorm normalized name: CARBOHYDRATE/ELECTROLYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-electrolyte solution (CHOc)
Trial: 21161666
Drug: Carbohydrate-electrolyte solution
RxNorm normalized name: CARBOHYDRATE/ELECTROLYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-electrolyte solution (CHO)
Trial: 19241334
Drug: Rowatinex, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rowatinex, 100 mg, 3 times per day
Trial: 15291124
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg tid for 4 days
Trial: 11304896
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg dose of atrasentan
Trial: 11304896
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dose of atrasentan
Trial: 11304896
Drug: 23.25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23.25 mg dose of atrasentan
Trial: 11304896
Drug: 139.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 139.5 mg dose of atrasentan
Trial: 11304896
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of atrasentan
Trial: 9385283
Drug: Nasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal salmon calcitonin (200 IU daily for 28 days)
Trial: 9113120
Drug: Tropisetron (Navoban)
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (Navoban) monotherapy
Trial: 9113120
Drug: All antiemetic
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All antiemetic treatments
Trial: 347574
Drug: Apomorphine (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (subcutaneous doses)
Trial: 31918760
Drug: Transdiagnostic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic treatment protocol using an adapted version of the Problem Management Plus (PM+) protocol, consisting of six 90-min sessions.
Trial: 30753642
Drug: Vaginal tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vaginal tenofovir (TFV) 1% gel
Trial: 28271493
Drug: Orbis' microsphere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbis' microsphere prednisone formulation
Trial: 28271493
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (Roxanne Laboratories)
Trial: 26095784
Drug: Ramucirumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab (8 mg/kg) every 2 weeks
Trial: 21975231
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no stem cell treatment)
Trial: 16899031
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg) or Placebo
Trial: 15205853
Drug: 7.2 mM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.2 mM sodium nitroprusside (SNP) solution (2.16 mg/ml)
Trial: 11348560
Drug: Spray-dried antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray-dried antioxidant supplement (30 g) for 2 weeks
Trial: 9421873
Drug: Bayesian solution
RxNorm normalized name: Babesia microti preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bayesian solution using BUGS implementation of Gibbs sampling
Trial: 9421873
Drug: Naive analyses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naive analyses using average risk in control and treatment groups
Trial: 3540836
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (similar volume of drug vehicle)
Trial: 27523436
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of resveratrol/day for 4 weeks
Trial: 12840088
Drug: CAF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF plus high-dose chemotherapy with cyclophosphamide and thiotepa and autologous hematopoietic stem-cell transplantation
Trial: 12840088
Drug: CAF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF plus high-dose chemotherapy and stem-cell transplantation
Trial: 10821295
Drug: Rosiglitazone 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 12 mg
Trial: 8690280
Drug: Octreotide (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (0.6 mg/24 hr)
Trial: 30418492
Drug: Adaptive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive treatment designs and Sequential Multiple Assignment Randomized Trial
Trial: 9524970
Drug: Antibiotic susceptibility
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic susceptibility
Trial: 8475837
Drug: Postoperative subconjunctival
RxNorm normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative subconjunctival 5-fluorouracil (5-FU) injections
Trial: 21837
Drug: Ca-containing antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca-containing antacid
Trial: 21837
Drug: Ca-free antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca-free antacid
Trial: 31896620
Drug: Omaveloxolone 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omaveloxolone 160 mg
Trial: 31623400
Drug: L-theanine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine (200 mg/day)